Non-Invasive Molecular Imaging of β-Adrenoceptors In Vivo: Perspectives for PET-Radioligands
Authors: Kopka, K.; Law, M. P.; Breyholz, H.- J.; Faust, A.; Holtke, C.; Riemann, B.; Schober, O.; Schafers, M.; Wagner, S.
Source: Current Medicinal Chemistry, Volume 12, Number 18, August 2005 , pp. 2057-2074(18)
Publisher: Bentham Science Publishers
Abstract:Recently, the spectrum of molecular imaging devices such as positron emission tomography (PET) was further expanded by the now clinically available combined imaging modalities such as PET-CT and the preclinically used small animal PET scanners. These are powerful tools that can bridge the gap between preclinical and clinical evaluation studies of new radiotracers for molecular imaging of healthy and diseased states in vivo.
The β-adrenoceptor (β-AR) radioligands discussed in this review represent a class of molecular probes for the non-invasive in vivo assessment of β-AR density eg. in the heart with PET. The β-AR radioligands (S)- [11C]CGP 12177 (1) or (S)-[11C]CGP 12388 (2) are currently investigated in clinical studies with PET. Additionally, subtype-selective b1-AR radioligands are used in preclinical research which show potential for the diagnostics of the "β1-AR organ" as such the heart can be defined. Non-invasive quantification of β-ARs could facilitate the accurate choice and control of therapeutic interventions. Here we summarize the state-ofthe- art of the radiochemistry of radioactive β-AR radioligands.
Keywords: adrenoceptor radioligand; diagnostics in nuclear medicine; molecular imaging; positron emission tomography pet; receptor imaging in vivo; scintigraphy; subtype-selective b-adrenoceptor radioligand
Document Type: Review Article
Affiliations: Department of Nuclear Medicine, Section Radiochemistry, University Hospital of the Westfalische Wilhelms-Universitat, Albert-Schweitzer-Str. 33, D-48149 Munster, Germany.
Publication date: August 2005
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.